Comprehensive CMO / CDMO Services: End-to-End Formulation Development & Advanced GMP Manufacturing
In a highly competitive global pharmaceutical landscape, accelerating time-to-market while maintaining uncompromising compliance is paramount. At PharpleQ Lifesciences, we operate as a premier, asset-light Contract Development and Manufacturing Organization (CDMO). We deliver integrated, one-stop, end-to-end solutions that bridge initial discovery phase chemistry with multi-ton commercial market supply.Our operations are centered exclusively at manufacturing sites carrying the industry's most stringent global regulatory credentials: US-FDA, EU-GMP, WHO-GMP, UK-MHRA, TGA, ANVISA, and PIC/S compliance.
Integrated Formulation Development (R&D to Pilot Scale)
Our pharmaceutical development program is anchored in the principles of Quality by Design (QbD) per ICH Q8(R2) guidelines. We systematically build quality into the dosage form, eliminating empirical formulation guesswork.
Pre-Formulation & Material Characterization
Active Pharmaceutical Ingredient (API) Profiling
- Exhaustive solid-state characterization including polymorph screening, particle size distribution (PSD) mapping, pKa/logP determination, and hygroscopicity evaluations.
Excipient Compatibility Matrices
- Isothermal stress testing and binary mixture stability profiling using advanced differential scanning calorimetry (DSC) and FT-IR to establish optimal non-interacting excipient baselines.
Advanced Drug Delivery Systems (Sustained, Targeted, & Amorphous)
Bioavailability Enhancement
- Specialized solubility modification frameworks for BCS Class II and Class IV molecules utilizing Hot-Melt Extrusion (HME) and Closed-Loop Solvent Spray Drying to construct stable amorphous solid dispersions (ASDs).
Controlled-Release Matrices
- Development of complex oral solid modifications, including erosion-controlled hydrophilic matrices, lipid-based vehicles, and functional multiparticulate systems using Fluid-Bed Wurster Coating technology.
Formulation Optimization via Design of Experiments (DoE)
Statistical Screening
- Deployment of multi-factorial designs (e.g., Plackett-Burman, Central Composite Designs) to evaluate the quantitative impact of variable factors (binder concentrations, compaction forces, process temperatures) on Critical Quality Attributes (CQAs).
Design Space Definition
- Delineation of the strict operational multidimensional combination of material attributes and process parameters that guarantee product compliance.
Commercial Advanced Manufacturing & Unit Operations
Our commercial manufacturing facilities utilize flexible, state-of-the-art machinery trains engineered to mitigate cross-contamination and handle highly potent compounds safely.Oral Solid Dosages (OSD) & Specialized Matrices
Granulation and Blending
- High-shear mixers coupled natively with fluid-bed dryers, and bin blenders up to 2000L capacity utilizing calculated scale factors for constant shear stress.
Multi-particulate Systems
- High-throughput fluid-bed Wurster systems optimized for multi-layer drug layering, seal-coating, and functional release membrane placement.
Compression and Encapsulation
- High-speed, automated rotary press operations fitted with automated weight-control loops and force-feeders to execute single-layer and bilayer compression profile matching.
Amorphous Solidifications
- Continuous Twin-Screw Extruders built to manage polymer melts under strict specific mechanical energy (SME) feedback control loops, alongside high-tonnage explosion-proof commercial spray dryers processing aqueous and organic solvent matrices under automated inert gas loops.
Sterile & Liquid Injections (Parenterals)
Aseptic Processing Lines
- Grade A isolation barriers and Restricted Access Barrier Systems (RABS) managing sterile liquid vial filling, lyophilization configurations, and terminal sterilization loops.
Complex Liquids
- Specialized compounding loops for uniform emulsions, nano-suspensions, and temperature-controlled lipid solutions.
Stringent Process Validation (PV) & Lifecycle Management
Aligned with the current three-stage lifecycle validation paradigm (FDA / ICH Q8, Q9, Q10, Q11), we guarantee process capability and reproducibility over the product lifecycle.
Stage 1: Process Design (QbD Development Window)
Defining the Manufacturing Operational Envelope
- We define the target boundaries of the commercial process through early laboratory and pilot scale-up studies. Knowledge gained during Section 1 (Formulation Development) is used to explicitly formulate the control strategy.
Risk Assessment Frameworks
- Early initial risk assessments are performed to identify which processing steps and raw material variables could derail batch parameters, establishing an interactive Critical Process Parameter (CPP) vs. Critical Quality Attribute (CQA) link matrix.
Process Dynamics & Limits (NOR vs. PAR)
- We establish the Normal Operating Ranges (NOR) and Proven Acceptable Ranges (PAR) for manufacturing variables (e.g., mixing times, extruder speeds, spray drying heat flux) to guarantee operational flexibility before entering commercial lots.
Stage 2: Process Performance Qualification (PPQ / PV Batches)
The Definitive 3-Batch Paradigm
- Execution of a minimum of three consecutive, commercial-scale GMP batches to formally demonstrate that the manufacturing process operates in a state of control.
Stratified Intra-Batch Sampling
- We implement rigorous sampling plans across production runs. For example, solid orals are sampled at a minimum of 20 distinct intervals during compression to challenge blend uniformity, weight distribution, hardness consistency, and content uniformity.
Critical Parameter Matrix Verification
- Real-time tracking of CPP variability against the pre-established Design Space, calculating intra-batch and inter-batch Process Capability Indexes (Cpk => 1.33).
Stage 3: Continued Process Verification (CPV)
Statistical Process Control (SPC)
- Post-validation commercial lots are continuously tracked using control charts (X-bar and R charts) for proactive trend detection.
Annual Product Reviews (APR / PQR)
- Comprehensive yearly evaluations of process deviations, out-of-specification (OOS) data, change controls, and stability trends to ensure long-term stability and regulatory compliance.
Scientifically Grounded Cleaning Validation Frameworks
To safely execute campaign manufacturing within multi-product facilities, we run a zero-tolerance cleaning validation program based on quantitative toxicological limits, eliminating cross-contamination risks.
Toxicological Limit Determination
ADE / PDE Calculations
- Limits are derived from absolute clinical data rather than arbitrary safety factors. We calculate the Acceptable Daily Exposure (ADE) and Permitted Daily Exposure (PDE) based on no-observed-adverse-effect levels (NOAEL).
MACO Calculation
- The Maximum Allowable Carryover (MACO) into the next product is calculated using the following formula:
(MACO=PDEprevious x MBSnext / MDDnext)
Where: PDEprevious = Permitted Daily Exporsure of previous product; MBSnext = Minimum Batch Size of next product; MDDnext = Maximum Daily Dose of next product.
Worst-Case Matrix Strategy
Product Grouping
- Products are evaluated and ranked in a dynamic risk matrix based on solubility, potency, toxicity, cleanability, and mechanical surface affinity. Validation runs are executed exclusively using the designated "worst-case" product to clear the entire line equipment train.
Sampling and Analytical Extraction
Quantitative Swab Protocols
- Swab sampling is performed on defined 100 cm² high-risk, critical hard-to-clean locations (e.g., filler nozzles, extruder dies, impeller blades) using validated recoveries (≥ 80%).
Rinse Liquid Analytics
- Total volume rinse methods supplement swab validation to verify inaccessible inner pipe geometries and transfer lines.
Ultra-Trace Analysis
- Samples are processed using highly sensitive, validated methods such as High-Performance Liquid Chromatography (HPLC) or Total Organic Carbon (TOC) with detection boundaries reaching parts-per-billion (ppb) sensitivity limits.
Analytical Method Development, Quality Control & Comprehensive CMC Stability
Our analytical testing laboratories run in direct synchronization with production timelines to provide comprehensive chemistry, manufacturing, and control (CMC) release testing under strict 21 CFR Part 11 Data Integrity controls.
Advanced Testing Portfolio
Chromatographic Characterization
- High-resolution HPLC/UHPLC systems, Gas Chromatography (GC) head-space analysis for residual solvent control, and Mass Spectrometry (LC-MS/MS) for trace nitrosamine and elemental impurity quantification.
Solid-State & Performance Physics
- X-ray Powder Diffraction (XRPD), Particle Size Distribution via Laser Diffraction, and automated dissolution profile testing matrices.
Method Transfer Protocols & Data Alignment (Lab-1 vs. Lab-2)
Every product moving to commercial release is subjected to the rigid, inter-laboratory analytical method transfer protocol defined in our technical frameworks:
Assay and Content Uniformity
- Strict comparison profiles demanding an absolute difference between Lab-1 (R&D) and Lab-2 (Commercial Site Control) of ≤ 2.0% alongside Two-Sample t-tests returning a p-value ≥ 0.05.
Related Substances
- Comparative profiles ensuring trace stability tracking within an absolute variance window of ≤ 0.05% for known impurities.
Dissolution Comparison
- Verification of identical in-vitro profile release kinetics demanding mathematical f₂ similarity scores strictly between 50 and 100.
ICH-Compliant Commercial Stability Registration Support
Walk-In Stability Chambers
- Fully automated, continuous 24/7 monitored environment chambers built with secondary redundant backup systems.
Mechanized Environmental Tracking
Execution of stability profiles matching global validation requirements:
- Zone II (Subtropical): 25°C ± 2°C / 60% ± 5% RH
- Zone IVa (Hot/Humid): 30°C ± 2°C / 65% ± 5% RH
- Zone IVb (Hot/Very Humid): 30°C ± 2°C / 75% ± 5% RH
- Accelerated Testing Matrix: 40°C ± 2°C / 75% ± 5% RH
Photostability Testing
- Fully compliant with ICH Q1B mandates, exposing product matrices to specified near-UV and visible light energy inputs to characterize light degradation pathways.
End-to-End Documentation, Dossier, & CMC Regulatory Support
- Master Regulatory Dossiers: Complete authoring of Module 3 (CMC) formatted strictly to electronic Common Technical Document (eCTD) structural demands.
- Formulation Development Reports (FDR): Detailed QbB documentation outlining parameters, risk-assessment strategies, and DoE design matrices.
- Validation Packages: Performance Qualification protocols detailing results across three consecutive, full-scale commercial manufacturing batches.
- Cleaning Validation Manuals: Definitive scientific data verifying Maximum Allowable Carryover (MACO) and toxicological safety limit alignments (ADE / PDE) via verified swab and rinse residue values.
- Analytical Validation Data Packages: Comprehensive analytical compilation documents proving linearity, accuracy, precision, and robustness per ICH Q2(R2) mandates.